Wave Life Sciences, Inc. (WVE)
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
- Symbol
- WVE
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $840.76M
- 52 week range
- 3.92 - 21.73
Valuation
- Share price
- $3.95 (close of 2026-09-23)
- P/E (TTM)
- -4.03x
- Price to book
- 1.85x
- Price to free cash flow
- -4.35x
- Enterprise value
- $393.75M
- Book value per share
- $2.35
Price performance
| Period | Change |
|---|
| 1 day | -7.28% |
| 5 days | -11.43% |
| 1 month | -25.33% |
| 3 months | -34.60% |
| 6 months | -66.01% |
| Year to date | -76.76% |
| 1 year | -42.17% |
| 3 years | -27.39% |
| 5 years | -35.03% |
| 10 years | -88.49% |
| All time | -75.31% |
Profitability and growth
- Return on equity
- -39.43%
- Return on assets
- -32.01%
- Return on capital employed
- -39.63%
- Net margin
- -478.33%
- EBITDA margin
- -496.04%
- Revenue growth
- -60.55%
- Net income growth
- -110.68%
- Free cash flow growth
- -23.85%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -22.97%
- Current ratio
- 9.99x
- Net debt to EBITDA
- 2.14x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $42.73M
- EBITDA
- $-211.94M
- Net income
- $-204.38M
- Earnings per share
- $-1.21
- Research and development
- $182.78M
- Shares outstanding
- 168.65M
Income statement by year
| Period end | Revenue | Net income | EPS |
|---|
| 2025-12-31 | $42.73M | $-204.38M | $-1.21 |
| 2024-12-31 | $108.30M | $-97.01M | $-0.70 |
| 2023-12-31 | $113.31M | $-57.51M | $-0.54 |
| 2022-12-31 | $3.65M | $-161.82M | $-2.05 |
| 2021-12-31 | $40.96M | $-122.25M | $-2.36 |
| 2020-12-31 | $20.08M | $-149.91M | $-3.82 |
| 2019-12-31 | $15.98M | $-193.64M | $-5.72 |
| 2018-12-31 | $14.41M | $-146.65M | $-5.06 |
| 2017-12-31 | $3.89M | $-101.98M | $-3.85 |
| 2016-12-31 | $1.09M | $-55.66M | $-2.44 |
Margins and returns by year
| Period end | Net margin | Return on equity |
|---|
| 2025-12-31 | -478.33% | -39.43% |
| 2024-12-31 | -89.57% | -46.30% |
| 2023-12-31 | -50.76% | -145.12% |
| 2022-12-31 | -4434.72% | 358.88% |
| 2021-12-31 | -298.42% | -376.16% |
| 2020-12-31 | -746.68% | -181.10% |
| 2019-12-31 | -1211.52% | -303.83% |
| 2018-12-31 | -1017.43% | -199.94% |
| 2017-12-31 | -2619.57% | -73.05% |
| 2016-12-31 | -5097.07% | -41.35% |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $602.07M |
| 2024-12-31 | $302.08M |
| 2023-12-31 | $200.35M |
| 2022-12-31 | $88.50M |
| 2021-12-31 | $150.56M |
| 2020-12-31 | $184.50M |
| 2019-12-31 | $147.16M |
| 2018-12-31 | $174.82M |
| 2017-12-31 | $142.50M |
| 2016-12-31 | $150.29M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-188.21M | $24.97M |
| 2024-12-31 | $-151.96M | $13.14M |
| 2023-12-31 | $-20.55M | $9.79M |
| 2022-12-31 | $-129.14M | $17.19M |
| 2021-12-31 | $-89.55M | $16.41M |
| 2020-12-31 | $-117.32M | $14.30M |
| 2019-12-31 | $-192.15M | $19.51M |
| 2018-12-31 | $-32.80M | $15.60M |
| 2017-12-31 | $-102.56M | $12.14M |
| 2016-12-31 | $-37.49M | $6.85M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-09
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-30 | Jun/2026 | - |
| 2026-04-28 | - | - |
| 2026-02-26 | - | - |
| 2025-11-10 | - | - |
| 2025-07-30 | - | - |
| 2025-05-08 | - | - |
| 2025-03-04 | - | - |
| 2024-11-12 | - | - |
Filings and sources
- Company website
- wavelifesciences.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades